Sign inSign up
Sign upSign in

GLP-1 Clinical Trials

Registered trials for the GLP-1 and metabolic compounds we track — semaglutide, tirzepatide, retatrutide, and more — pulled from ClinicalTrials.gov and tagged to each compound. 152 of 284 are currently active.

v1.0 · Updated 2026-07-12 · Source: ClinicalTrials.gov API v2 · 284 rows

Download CSVView JSONBrowse the directory
TrialCompoundsPhaseStatusEnroll.Start
Metabolic Surgery for Atrial Fibrillation EliminationNCT07027969Liraglutide, DulaglutidePhase 4Not yet recruiting1002026-11-01
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891DulaglutidePhase 2Not yet recruiting602026-10
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Dulaglutide, OrforglipronPhase 3Not yet recruiting1702026-09
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740Semaglutide, CagrilintidePhase 2Withdrawn02026-08-27
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613CagrilintidePhase 3Not yet recruiting802026-08-04
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderNCT07693608TirzepatidePhase 2Not yet recruiting452026-08-01
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNCT07676331TirzepatidePhase 2Not yet recruiting1682026-08-01
Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248TirzepatidePhase 3Not yet recruiting152026-08-01
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese ParticipantsNCT07671391TirzepatidePhase 2Not yet recruiting602026-08
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid ObesityNCT07668765Tirzepatide—Not yet recruiting1002026-08
Imaging in Semaglutide StudyNCT07695454Semaglutide—Not yet recruiting102026-07-15
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerNCT07627191SemaglutideEARLY_Phase 1Not yet recruiting302026-07-10
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial CancerNCT07349641TirzepatidePhase 2Not yet recruiting552026-07-06
Free Fatty Acid Effects In Type 2 DiabetesNCT07677995Semaglutide—Enrolling by invitation602026-07
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes MellitusNCT07563699SemaglutidePhase 1/Phase 2Not yet recruiting242026-07
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059SemaglutidePhase 1Not yet recruiting202026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol SecretionNCT07573163TirzepatidePhase 2Not yet recruiting342026-07
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307OrforglipronPhase 3Not yet recruiting1302026-07
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766Semaglutide, CagrilintidePhase 3Withdrawn02026-06-22
Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNCT07382024Tirzepatide—Not yet recruiting2002026-06-16
Brain Plasticity and GLP-1 Receptor Agonist Treatment for ObesityNCT07021937SemaglutidePhase 3Not yet recruiting1202026-06-15
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese ParticipantsNCT07673900SemaglutidePhase 1Recruiting622026-06-15
Tirzepatide in MetALDNCT07046819TirzepatidePhase 2Recruiting1202026-06-11
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021SemaglutidePhase 2Recruiting2302026-06-09
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484TirzepatidePhase 4Recruiting302026-06-08
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical ClockNCT07444073Semaglutide, Tirzepatide—Not yet recruiting4402026-06-01
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and ReinitiationNCT07387796Tirzepatide—Recruiting402026-06
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587CagrilintidePhase 1Recruiting1142026-05-29
Genetic, Microbiological and Behavioral Factors in ObesityNCT07650149Tirzepatide—Recruiting2002026-05-23
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910TirzepatidePhase 2Recruiting2042026-05-22
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Semaglutide, CagrilintidePhase 3Recruiting25002026-05-21
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)NCT07559500TirzepatidePhase 1Recruiting1762026-05-20
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052CagrilintidePhase 1Active not recruiting502026-05-20
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018CagrilintidePhase 1Recruiting2342026-05-18
Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityNCT07574723Tirzepatide—Recruiting682026-05-15
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisNCT06726577LiraglutidePhase 1/Phase 2Recruiting602026-05-10
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437LiraglutidePhase 4Not yet recruiting1202026-05-01
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088DulaglutidePhase 4Not yet recruiting4682026-05
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953CagrilintidePhase 1Recruiting1202026-04-30
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisNCT07497399ExenatidePhase 2Recruiting1202026-04-28
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.NCT07653412Semaglutide, Tirzepatide—Recruiting2202026-04-22
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954SemaglutidePhase 2Recruiting2702026-04-17
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195CagrilintidePhase 1Recruiting1002026-04-10
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334Liraglutide, OrforglipronPhase 2Recruiting202026-04-07
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998SemaglutidePhase 2Recruiting2002026-03-26
A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846TirzepatidePhase 1/Phase 2Recruiting1562026-03-02
Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight LossNCT07685834Tirzepatide—Active not recruiting302026-02-27
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447RetatrutidePhase 2Recruiting3002026-02-15
The Evira Study: Additional Support During Obesity TreatmentNCT06836284Liraglutide—Recruiting402026-02-13
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.NCT07619508Semaglutide, Tirzepatide—Completed1000002026-02-10
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560CagrilintidePhase 1Recruiting1002026-02-09
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631Dulaglutide—Completed3000002026-02-03
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618Semaglutide, Tirzepatide, Dulaglutide—Completed600002026-01-27
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)NCT07390110Semaglutide—Active not recruiting256642026-01-24
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415RetatrutidePhase 3Active not recruiting6002026-01-24
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495Semaglutide, Dulaglutide—Completed1200002026-01-20
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080ExenatideEARLY_Phase 1Recruiting92026-01-20
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285CagrilintidePhase 3Recruiting4602026-01-08
Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139Liraglutide—Enrolling by invitation1250002026-01-01
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813DulaglutidePhase 1Active not recruiting202025-12-29
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041DulaglutidePhase 2/Phase 3Recruiting1302025-12-17
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNCT07276763Dulaglutide—Not yet recruiting165092025-12-10
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390OrforglipronPhase 3Recruiting71402025-12-01
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)NCT07247084TirzepatidePhase 4Recruiting30002025-11-24
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719RetatrutidePhase 3Active not recruiting2502025-11-17
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVNCT06935838TirzepatidePhase 2Completed122025-11-12
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816LiraglutidePhase 1Recruiting752025-11-07
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642CagrilintidePhase 3Active not recruiting3002025-11-05
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759CagrilintidePhase 3Active not recruiting3302025-11-05
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593OrforglipronPhase 3Recruiting12052025-10-31
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Tirzepatide, RetatrutidePhase 3Recruiting45002025-10-15
A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539DulaglutidePhase 3Not yet recruiting5462025-09-30
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884OrforglipronPhase 3Recruiting10002025-09-30
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086CagrilintidePhase 1Recruiting802025-09-26
Study of Tirzepatide for Recovery and Alcohol Use ManagementNCT06727331TirzepatidePhase 2Recruiting202025-09-15
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)NCT07188545Dulaglutide, Exenatide—Active not recruiting232800002025-09-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471OrforglipronPhase 3Recruiting8002025-09-15
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872SemaglutidePhase 2Active not recruiting2402025-08-19
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityNCT07091500Semaglutide—Recruiting402025-08-11
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286DulaglutidePhase 1/Phase 2Enrolling by invitation502025-08-04
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyNCT06903923LiraglutidePhase 2Recruiting1202025-07-31
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099TirzepatidePhase 3Recruiting2902025-06-26
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086TirzepatidePhase 3Recruiting3502025-06-26
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829LiraglutidePhase 2Recruiting1292025-06-17
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432CagrilintidePhase 1Recruiting1442025-06-12
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846RetatrutidePhase 1Completed802025-06-06
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667CagrilintidePhase 3Active not recruiting6092025-06-03
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859RetatrutidePhase 1Recruiting952025-06-02
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093RetatrutidePhase 3Recruiting5862025-05-29
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962DulaglutidePhase 4Active not recruiting5042025-05-26
Tirzepatide vs Liraglutide in BoneNCT07094568Liraglutide—Recruiting722025-05-23
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472OrforglipronPhase 3Active not recruiting6002025-05-19
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792OrforglipronPhase 3Active not recruiting12002025-05-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459OrforglipronPhase 3Active not recruiting6002025-05-15
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06937203TirzepatidePhase 1/Phase 2Recruiting1502025-05-09
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)NCT07029009LiraglutidePhase 2Recruiting502025-05-08
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNCT07055607Semaglutide—Enrolling by invitation12502025-05-01
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminNCT07109700DulaglutidePhase 2Recruiting2162025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435OrforglipronPhase 3Active not recruiting4872025-04-30
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422OrforglipronPhase 3Active not recruiting9742025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530OrforglipronPhase 3Active not recruiting4872025-04-30
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Semaglutide, TirzepatidePhase 2Recruiting2402025-03-28
Effect of Tirzepatide on Brown Adipose Tissue in ObesityNCT06893211TirzepatidePhase 2Completed342025-03-18
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026TirzepatidePhase 4Recruiting2002025-03-06
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268RetatrutidePhase 3Active not recruiting6432025-03-05
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051OrforglipronPhase 1Completed1202025-02-17
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449CagrilintidePhase 3Active not recruiting4002025-02-10
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802RetatrutidePhase 1Completed302025-02-03
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869CagrilintidePhase 2Active not recruiting1422025-01-29
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122DulaglutidePhase 3Recruiting552025-01-10
Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With ObesityNCT07638592Tirzepatide—Completed912025-01-01
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435Liraglutide, DulaglutidePhase 4Active not recruiting602024-12-21
Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantNCT05670379ExenatidePhase 1Completed242024-12-20
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsNCT06704763OrforglipronPhase 1Completed272024-12-06
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538TirzepatidePhase 1/Phase 2Recruiting1802024-12-04
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307CagrilintidePhase 1Completed182024-12-02
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaNCT07370922DulaglutidePhase 2Completed802024-11-22
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939OrforglipronPhase 3Recruiting1502024-11-18
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549OrforglipronPhase 3Recruiting1252024-11-18
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411CagrilintidePhase 3Active not recruiting10232024-11-05
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383RetatrutidePhase 3Active not recruiting8002024-11-01
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929Dulaglutide—Completed700002024-11-01
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045OrforglipronPhase 3Active not recruiting6002024-10-22
Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.NCT06888167Exenatide—Recruiting402024-10-14
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryNCT06500143Dulaglutide—Completed942024-10-09
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353SemaglutidePhase 1Recruiting302024-10-01
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063Dulaglutide—Completed8871322024-10-01
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718Dulaglutide—Completed446712024-10-01
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283TirzepatidePhase 3Completed2812024-09-30
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515Exenatide—Recruiting240002024-09-30
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 AgonistsNCT06640972Semaglutide, TirzepatidePhase 2Completed682024-09-27
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2NCT06396416SemaglutidePhase 4Recruiting602024-09-26
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916OrforglipronPhase 3Completed3762024-09-13
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNCT06449235ExenatidePhase 4Not yet recruiting9382024-09
Exenatide For Reducing the Reinforcing Effects of CocaineNCT06252623ExenatidePhase 1Withdrawn02024-08-01
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527DulaglutidePhase 4Completed692024-07-31
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966Dulaglutide, ExenatidePhase 3Active not recruiting6002024-07-17
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsNCT06254014ExenatidePhase 3Active not recruiting2702024-07-10
Risk Factors Affect Weight Loss Outcomes After Treatment.NCT06482411Liraglutide—Completed36022024-06-27
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187CagrilintidePhase 3Completed3002024-06-24
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277TirzepatidePhase 3Recruiting3002024-06-03
Diabetes Islet Preservation Immune TreatmentNCT02586831ExenatidePhase 1/Phase 2Withdrawn02024-06-01
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130CagrilintidePhase 2Completed2702024-05-20
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761CagrilintidePhase 1Completed1582024-05-06
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390RetatrutidePhase 3Active not recruiting100002024-04-30
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660RetatrutidePhase 3Completed5372024-04-10
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641Liraglutide—Completed3002024-04-08
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086DulaglutidePhase 3Completed6322024-04-08
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372CagrilintidePhase 2Completed6262024-04-01
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219LiraglutidePhase 4Active not recruiting302024-03-30
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161CagrilintidePhase 3Completed2742024-03-26
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528RetatrutidePhase 1Completed852024-03-20
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461DulaglutidePhase 4Recruiting3722024-03-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174CagrilintidePhase 3Completed1892024-03-19
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603RetatrutidePhase 3Active not recruiting3202024-03-15
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGHNCT06003153SemaglutidePhase 4Recruiting1252024-03-12
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504CagrilintidePhase 1Completed342024-02-27
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877CagrilintidePhase 1Completed622024-02-23
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722RetatrutidePhase 3Active not recruiting12502024-02-21
A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092CagrilintidePhase 1Completed1642024-02-15
A Study of HS-20094 in Patients With T2DMNCT06901648DulaglutidePhase 2Completed2752024-02-06
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908LiraglutidePhase 3Completed1502024-01-30
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152LiraglutideEARLY_Phase 1Suspended302024-01-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969CagrilintidePhase 3Completed10242024-01-16
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108OrforglipronPhase 3Completed9622024-01-10
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622OrforglipronPhase 1Completed502024-01-02
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMNCT06256419Exenatide—Recruiting3002024-01-01
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141Liraglutide—Completed1282023-12-20
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusNCT06148649DulaglutidePhase 2Completed2342023-12-10
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437CagrilintidePhase 3Completed8092023-11-27
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956TirzepatidePhase 2Recruiting14812023-11-17
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311OrforglipronPhase 3Completed5462023-11-10
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese SubjectsNCT06247748ExenatidePhase 1Completed282023-10-19
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482OrforglipronPhase 1Completed102023-10-19
Semaglutide Therapy for Alcohol Reduction (STAR)NCT06015893SemaglutidePhase 2Recruiting802023-10-17
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667TirzepatidePhase 3Active not recruiting1602023-10-16
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707DulaglutidePhase 2Suspended472023-10-05
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004OrforglipronPhase 3Completed4012023-09-28
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540Semaglutide, CagrilintidePhase 3Completed27342023-09-27
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221OrforglipronPhase 3Completed16982023-09-22
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094Liraglutide, Dulaglutide, Exenatide—Recruiting2502023-09-15
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational DiabetesNCT05569772SemaglutidePhase 3Recruiting2522023-09-14
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826RetatrutidePhase 1Completed462023-09-12
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryNCT07374445LiraglutidePhase 4Completed1002023-09-01
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465RetatrutidePhase 1Completed572023-08-29
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848CagrilintidePhase 3Completed3002023-08-15
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940OrforglipronPhase 3Completed5592023-08-09
A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)NCT05984238Semaglutide—Completed332023-08-03
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367RetatrutidePhase 3Completed4452023-08-01
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151RetatrutidePhase 2Completed1462023-07-20
A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096RetatrutidePhase 1Completed852023-07-18
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560RetatrutidePhase 1Completed432023-07-13
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138OrforglipronPhase 1Completed242023-07-13
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079RetatrutidePhase 3Active not recruiting10002023-07-11
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066RetatrutidePhase 3Completed23352023-07-10
Preoperative Weight Loss for Open Abdominal Wall ReconstructionNCT05925959Liraglutide—Recruiting2582023-06-19
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032OrforglipronPhase 1Completed292023-06-13
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903OrforglipronPhase 3Active not recruiting31272023-06-05
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620OrforglipronPhase 3Completed16132023-06-05
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045RetatrutidePhase 3Active not recruiting19462023-05-30
Effects of GH and Lirglutide on AgRPNCT05681299LiraglutidePhase 4Recruiting402023-05-01
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238OrforglipronPhase 1Completed522023-04-26
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesNCT05482789ExenatidePhase 4Recruiting132023-04-12
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104CagrilintidePhase 1Completed322023-04-05
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925CagrilintidePhase 3Completed3312023-04-03
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421OrforglipronPhase 3Completed27492023-04-03
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755CagrilintidePhase 3Active not recruiting71012023-03-01
Clinical Study of 18F-Exendin-4 in InsulinomaNCT07340437Exenatide—Completed202023-02-01
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519CagrilintidePhase 3Completed12002023-02-01
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249LiraglutidePhase 4Completed5002023-01-19
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129DulaglutidePhase 3Completed6232023-01-10
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaNCT05659537DulaglutidePhase 4Completed2122022-12-29
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800ExenatidePhase 2Completed1402022-12-07
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039DulaglutidePhase 4Completed2822022-11-30
Effects of Glucagon-like-Peptide-1 Analogues on SexualityNCT05598008Liraglutide—Completed852022-11-25
A Trial to Determine the Efficacy and Safety of Presendin in IIHNCT05347147ExenatidePhase 3Terminated142022-11-18
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseNCT05616013SemaglutidePhase 2Completed5072022-11-16
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957RetatrutidePhase 1Completed292022-11-16
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796CagrilintidePhase 3Active not recruiting34002022-11-01
A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231RetatrutidePhase 1Completed322022-10-24
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsNCT05573230OrforglipronPhase 1Completed322022-10-17
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529Liraglutide—Active not recruiting3962022-10-08
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892Liraglutide, DulaglutidePhase 4Recruiting60002022-09-26
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionNCT05371496SemaglutidePhase 4Enrolling by invitation812022-09-06
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126OrforglipronPhase 1Completed262022-08-01
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232RetatrutidePhase 1Completed322022-07-08
Young Adults With Early-onset Obesity Treated With SemaglutideNCT05574439SemaglutidePhase 4Completed2462022-05-30
A Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05313802OrforglipronPhase 1Completed722022-05-26
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104ExenatidePhase 2Recruiting1102022-05-25
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089OrforglipronPhase 1Completed392022-05-17
Lifestyle Counseling and Medication for Adolescent Weight ManagementNCT04873245SemaglutidePhase 2Completed1202022-03-15
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseNCT05254418DulaglutidePhase 2Completed72022-03-15
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes MellitusNCT05662189Exenatide—Recruiting702022-03-15
Adiponectin in Patients With Metabolic DisordersNCT07539584Liraglutide—Completed1302022-03-01
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 DiabetesNCT04307797ExenatidePhase 4Completed102022-01-18
A Multiple-Dose Study of LY3502970 in Healthy ParticipantsNCT05110794OrforglipronPhase 1Completed342021-11-05
A Multiple Dose Study of LY3502970 in Healthy ParticipantsNCT05051566OrforglipronPhase 1Completed262021-09-16
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802ExenatidePhase 4Completed422021-09-13
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575CagrilintidePhase 2Completed922021-08-02
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917Liraglutide, Dulaglutide, Exenatide—Active not recruiting7814302021-08-01
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272DulaglutidePhase 2Recruiting302021-07-16
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078CagrilintidePhase 1Completed402021-07-07
Comparison of Type 2 Diabetes Pharmacotherapy RegimensNCT05073692Exenatide—Completed2419812021-07-01
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT04952779Liraglutide—Completed7502021-06-02
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208RetatrutidePhase 1Completed642021-05-24
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760RetatrutidePhase 2Completed3382021-05-20
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396SemaglutidePhase 3Completed18402021-05-18
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785RetatrutidePhase 2Completed2812021-05-13
Exenatide-test for Diagnosing Endogenous Hyperinsulinemic HypoglycemiaNCT04909333Exenatide—Completed292021-04-29
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181SemaglutidePhase 3Active not recruiting12052021-04-01
Combined Active Treatment in Type 2 Diabetes With NASHNCT04639414SemaglutidePhase 4Completed1922021-03-26
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082LiraglutidePhase 3Active not recruiting782021-03-04
Brain Activation and Satiety in Children 2NCT04520490ExenatidePhase 3Active not recruiting632021-01-28
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844LiraglutidePhase 4Recruiting802020-11-01
A Study of LY3502970 in Participants With Type 2 DiabetesNCT04426474OrforglipronPhase 1Completed682020-10-08
Exenatide Once-weekly as a Treatment for Multiple System AtrophyNCT04431713ExenatidePhase 2Completed502020-09-16
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433Tirzepatide, DulaglutidePhase 3Completed132992020-05-29
A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNCT04154072ExenatidePhase 2Completed2552020-02-27
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969ExenatidePhase 3Completed1942020-01-20
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802RetatrutidePhase 1Completed722019-12-18
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075SemaglutidePhase 2Recruiting1042019-07-24
A Study of LY3502970 in Healthy ParticipantsNCT03929744OrforglipronPhase 1Completed1332019-06-12
Imaging Pituitary ActiVation by ExendinNCT03923114Exenatide—Completed202019-05-23
Liraglutide Effect in Atrial FibrillationNCT03856632LiraglutidePhase 4Active not recruiting602019-03-18
A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630RetatrutidePhase 1Completed452019-03-13
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related DiseaseNCT06725693Exenatide—Recruiting5002019-02-01
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001Liraglutide, Dulaglutide—Completed422018-04-16
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseNCT03492580Dulaglutide, Exenatide—Completed7145822018-02-22
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their CombinationNCT03878706Liraglutide, MOTS-c—Recruiting2402017-11-03
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyNCT02860923ExenatidePhase 3Completed422017-01-11
Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500LiraglutidePhase 4Active not recruiting282016-11
Pharmacogenomics of GLP1 Receptor AgonistsNCT05762744ExenatidePhase 1Terminated632016-06-01
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsNCT02773355Liraglutide—Completed272016-05-16
GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryNCT02673931Exenatide—Active not recruiting14002016-02
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeNCT02251431ExenatidePhase 3Completed572015-11
Liver and Fat Regulation in Overweight Adolescent GirlsNCT02157974ExenatidePhase 2/Phase 3Completed922014-08
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesNCT02674893LiraglutidePhase 4Terminated482014-02-04
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesNCT01794143LiraglutidePhase 3Completed78502013-05
Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismNCT02721888LiraglutidePhase 4Terminated1272012-07-10
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese DiabeticsNCT02042664ExenatidePhase 3Completed442011-01
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMNCT01107717ExenatidePhase 4Completed3182009-01
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolNCT00679042ExenatidePhase 3Active not recruiting212007-09-05
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationNCT07677865Semaglutide, Tirzepatide, Liraglutide—Completed2138912007-01-01
Provide Pre-approval Expanded Access of LY3437943NCT07629401Retatrutide—Available——

Citation: Synptide GLP-1 Clinical Trials, v1.0(synptide.com/datasets), sourced from ClinicalTrials.gov (public domain). The Synptide compound tagging is licensed CC BY 4.0. Registry data can lag real-world status — confirm on the source record before relying on it.